Biogen cut its annual profit forecast on Thursday, as it expects to take a hit of $1.25 per share from R&D related charges tied to certain acquisitions in the fourth quarter.
A gene on the X chromosome revs up inflammation in the female brain, which may explain why rates of multiple sclerosis are ...
One of TV’s most famous fictional families is reuniting on stage for the first time in decades, and it’s for a cause dear to ...
Because of how unpredictable MS symptom flares can be, columnist Desiree Lama often finds herself living a sheltered life.
The price of Rebif has increased four times faster than the rate of inflation, with Kay's insurer deciding to stop covering ...
The stars of the hit 1980s and 90s sitcom “Married with Children” are set to reunite early next year and it’s for a good ...
Bionxt launched the final animal study needed to prepare for human testing of BNT23001, its under-the-tongue version of ...
TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated ...
TG Therapeutics, Inc. (NASDAQ: TGTX), announced today that enrollment has completed in the randomized cohort of the Phase 3 ENHANCE trial evaluating a consolidated Day 1 and Day 15 dosing schedule for ...
An event like this takes significant planning, teamwork, and collaboration to provide a safe and successful ride. The ...
TG Therapeutics (($TGTX)) announced an update on their ongoing clinical study. Study Overview: TG Therapeutics is conducting a Phase 3 study ...
Cabaletta Bio, Inc. (($CABA)) announced an update on their ongoing clinical study. RESET-MS is a Phase 1/2 open-label study conducted by Cabaletta ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback